Comments
A new clinical trial in Argentina has revealed that convalescent plasma therapy given to patients suffering from severe pneumonia as one of the repercussions of Covid-19 seems to be little effective.
The study noted that the therapy that involves sharing antibodies of Covid-19 recovered patients with critically-ill coronavirus patients did not significantly improve health or reduce the risk of death.
The findings of the study were published in The New England Journal of Medicine.
Methodology
For the study, the researchers randomly assigned hospitalised adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo.
Also read: High blood sugar lethal for Covid-19, even for non-diabetics: Study
Results
A total of 228 patients were assigned to receive convalescent plasma and 105 to receive a placebo. Researchers followed the patients for 30 days. However, they noted no significant difference between the convalescent plasma group and the placebo group in the distribution of clinical outcomes.
Overall mortality was 10.96 per cent in the convalescent plasma group and 11.43 per cent in the placebo group, for a risk difference of −0.46 percentage points.
Also read: Poorest will be trampled in stampede for vaccines, cautions WHO chief
Total SARS-CoV-2 antibody titers tended to be higher in the convalescent plasma group on day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups, read the paper.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.